Literature DB >> 33863829

Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimation.

Lisa K Torres1, Katherine L Hoffman2, Clara Oromendia2, Ivan Diaz2, John S Harrington1, Edward J Schenck1, David R Price1, Luis Gomez-Escobar1, Angelica Higuera3, Mayra Pinilla Vera3, Rebecca M Baron3, Laura E Fredenburgh3, Jin-Won Huh4, Augustine M K Choi1, Ilias I Siempos5,6.   

Abstract

BACKGROUND: Although acute respiratory distress syndrome (ARDS) is associated with high mortality, its direct causal link with death is unclear. Clarifying this link is important to justify costly research on prevention of ARDS.
OBJECTIVE: To estimate the attributable mortality, if any, of ARDS.
DESIGN: First, we performed a systematic review and meta-analysis of observational studies reporting mortality of critically ill patients with and without ARDS matched for underlying risk factor. Next, we conducted a survival analysis of prospectively collected patient-level data from subjects enrolled in three intensive care unit (ICU) cohorts to estimate the attributable mortality of critically ill septic patients with and without ARDS using a novel causal inference method.
RESULTS: In the meta-analysis, 44 studies (47 cohorts) involving 56 081 critically ill patients were included. Mortality was higher in patients with versus without ARDS (risk ratio 2.48, 95% CI 1.86 to 3.30; p<0.001) with a numerically stronger association between ARDS and mortality in trauma than sepsis. In the survival analysis of three ICU cohorts enrolling 1203 critically ill patients, 658 septic patients were included. After controlling for confounders, ARDS was found to increase the mortality rate by 15% (95% CI 3% to 26%; p=0.015). Significant increases in mortality were seen for severe (23%, 95% CI 3% to 44%; p=0.028) and moderate (16%, 95% CI 2% to 31%; p=0.031), but not for mild ARDS.
CONCLUSIONS: ARDS has a direct causal link with mortality. Our findings provide information about the extent to which continued funding of ARDS prevention trials has potential to impart survival benefit. PROSPERO REGISTRATION NUMBER: CRD42017078313. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ARDS; clinical epidemiology; critical care

Mesh:

Year:  2021        PMID: 33863829     DOI: 10.1136/thoraxjnl-2020-215950

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  3 in total

1.  Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial.

Authors:  Andrew James Boyle; Peter Ferris; Ian Bradbury; John Conlon; Manu Shankar-Hari; Angela J Rogers; Cecilia M O'Kane; Daniel F McAuley
Journal:  Crit Care       Date:  2022-06-07       Impact factor: 19.334

2.  Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study.

Authors:  Evdokia Gavrielatou; Katerina Vaporidi; Vasiliki Tsolaki; Nikos Tserlikakis; George E Zakynthinos; Eleni Papoutsi; Aikaterini Maragkuti; Athina G Mantelou; Dimitrios Karayiannis; Zafeiria Mastora; Dimitris Georgopoulos; Epaminondas Zakynthinos; Christina Routsi; Spyros G Zakynthinos; Edward J Schenck; Anastasia Kotanidou; Ilias I Siempos
Journal:  Respir Res       Date:  2022-04-14

3.  The ROCK-ezrin signaling pathway mediates LPS-induced cytokine production in pulmonary alveolar epithelial cells.

Authors:  Ning Ding; Pibao Li; Huiqing Li; Yunlong Lei; Zengzhen Zhang
Journal:  Cell Commun Signal       Date:  2022-05-12       Impact factor: 7.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.